Patients with undiagnosed sleep disordered breathing and hypertrophic cardiomyopathy may have subclinical myocardial injury.

Serena Williams has endorsed GLP-1 medications, raising questions regarding their stigma and performance-enhancing potential for athletes.

A scientific statement regarding targeted nursing interventions in rural settings to improve stroke care has been published by the AHA.

The FDA has granted Fast Track designation to VS-041, an investigational therapy for the treatment of heart failure with preserved ejection fraction.

For patients who have undergone successful catheter ablation for atrial fibrillation, treatment with rivaroxaban does not offer superior stroke protection versus aspirin.

The FDA has approved Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

Adults with elevated levels of 3 biomarkers for heart disease have nearly triple the risk for heart attack over 15 years compared with adults without elevated levels.

Nearly all adults with chronic kidney disease would benefit from a systolic blood pressure target of less than 120 versus less than 140 mm Hg.

Researchers sought to determine the most appropriate P2Y12 inhibitor therapy in patients with acute coronary syndrome.

For adults with type 2 diabetes and/or overweight/obesity and high triglycerides, GLP-1RAs are not associated with pancreatitis.

The FDA has expanded the approval of Thrombate III to include pediatric patients with hATd to treat and prevent thromboembolism.

In patients with ACS receiving PCI, periprocedural GLP-1RA therapy is associated with decreased mortality risk.